Efficacy and Safety of Combining Apremilast 30mg Bid With Narrowband UVB in the Treatment of Moderate-to-severe Plaque Psoriasis

Trial Profile

Efficacy and Safety of Combining Apremilast 30mg Bid With Narrowband UVB in the Treatment of Moderate-to-severe Plaque Psoriasis

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2016

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jul 2016 Status changed from recruiting to completed.
    • 27 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2015 to 1 Feb 2016.
    • 27 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Oct 2015 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top